About Concordia International Corp (TSE:CXR)
Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: TSE:CXR
- CUSIP: N/A
- Web: concordiarx.com
- Market Cap: C$36.82 million
- Outstanding Shares: 51,143,000
- 50 Day Moving Avg: C$1.49
- 200 Day Moving Avg: C$1.72
- 52 Week Range: C$0.70 - C$7.39
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: C$677.25 million
- Price / Sales: 0.05
- Book Value: C($27.60) per share
- Price / Book: -0.03
- EBITDA: C$326.58 million
- Net Margins: -628.57%
- Return on Assets: -130.11%
- Average Volume: 125,538 shs.
- Short Ratio: 0.8
Frequently Asked Questions for Concordia International Corp (TSE:CXR)
What is Concordia International Corp's stock symbol?
Concordia International Corp trades on the Toronto Stock Exchange (TSX) under the ticker symbol "CXR."
How were Concordia International Corp's earnings last quarter?
Concordia International Corp (TSE:CXR) posted its earnings results on Thursday, August, 13th. The company reported $1.04 earnings per share for the quarter, missing the consensus estimate of $1.06 by $0.02. The business had revenue of $95.34 million for the quarter, compared to the consensus estimate of $87.41 million. View Concordia International Corp's Earnings History.
When will Concordia International Corp make its next earnings announcement?
Where is Concordia International Corp's stock going? Where will Concordia International Corp's stock price be in 2017?
4 brokers have issued 12-month price objectives for Concordia International Corp's shares. Their predictions range from C$13.50 to C$13.50. On average, they expect Concordia International Corp's share price to reach C$13.50 in the next twelve months. View Analyst Ratings for Concordia International Corp.
Who are some of Concordia International Corp's key competitors?
Some companies that are related to Concordia International Corp include Trillium Therapeutics (TRIL), Aevi Genomic Medicine (GNMX), Ohr Pharmaceuticals (OHRP), Can Fite Biopharma Ltd (CANF), Can Fite Biopharma Ltd (CANF), Soligenix (SNGX), Soligenix (SNGX), Mateon Therapeutics (MATN), Senesco Technologies (SVON), Windtree Therapeutics (WINT), Affymax (AFFY), Tetralogic Pharmaceuticals Corp (TLOG), CSL Limited (CSL), Cubist Pharmaceuticals (CBST), Dendreon (DNDN), DNIB Unwind (BIND), Durata Therapeutics (DRTX) and Epirus Biopharmaceuticals (EPRS).
Who are Concordia International Corp's key executives?
Concordia International Corp's management team includes the folowing people:
- Wayne Kreppner, President, Chief Operating Officer
- Allan Oberman, Chief Executive Officer, Director
- David J. Price, Chief Financial Officer
- Graeme Duncan, President - Company's International Segment
- Arijit Mookerjee, Managing Director, Chief Financial Officer - Operations
- Adeel Ahmad, Chief Financial Officer of AMCo
- Francesco Tallarico, Chief Legal Officer and Secretary
- Jordan M. Kupinsky J.D., Non-Executive Independent Chairman of the Board
- Douglas N. Deeth, Independent Director
- Rochelle Fuhrmann, Independent Director
How do I buy Concordia International Corp stock?
Shares of Concordia International Corp and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Concordia International Corp's stock price today?
MarketBeat Community Rating for Concordia International Corp (TSE CXR)MarketBeat's community ratings are surveys of what our community members think about Concordia International Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Concordia International Corp stock can currently be purchased for approximately C$0.72.
Earnings History for Concordia International Corp (TSE:CXR)Earnings History by Quarter for Concordia International Corp (TSE CXR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/6/2017|| || || || || || || || |
|8/13/2015||Q2||C$1.06||C$1.04||C$87.41 million||C$95.34 million||View||Listen|
|8/13/2014||C$0.19||C($0.03)||C$24.42 million||C$28.49 million||View||N/A|
Earnings Estimates for Concordia International Corp (TSE:CXR)
Current Year EPS Consensus Estimate: $0.66 EPS
Dividend History by Quarter for Concordia International Corp (TSE CXR)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Concordia International Corp (TSE:CXR)Insider Trades by Quarter for Concordia International Corp (TSE:CXR)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/25/2017||Erin Colleen O'neil||Director||Sell||191||C$1.74||C$332.34|
|5/16/2017||Graeme Neville Duncan||Director||Sell||7,065||C$1.91||C$13,494.15|
|2/1/2016||Mark Laurence Thompson||Director||Buy||60||C$28.77||C$1,726.20|
|11/17/2015||Wayne Walter Kreppner||Insider||Buy||3,000||C$43.67||C$131,010.00|
|11/16/2015||Mark Laurence Thompson||Director||Buy||23,150||C$43.36||C$1,003,702.98|
|7/17/2015||Wayne Walter Kreppner||Insider||Sell||4,800||C$103.00||C$494,400.00|
|6/26/2015||Robert Steven Altman||Insider||Sell||62,500||C$93.93||C$5,870,893.75|
|5/27/2015||Saldanha Adrian De||Insider||Buy||1,000||C$80.61||C$80,610.00|
|10/31/2014||James Christopher Reebals||Director||Sell||7,500||C$37.25||C$279,360.75|
|10/30/2014||James Christopher Reebals||Director||Sell||7,500||C$37.06||C$277,926.75|
|10/29/2014||James Christopher Reebals||Director||Sell||5,000||C$37.07||C$185,336.50|
Headline Trends for Concordia International Corp (TSE:CXR)
Latest Headlines for Concordia International Corp (TSE:CXR)
Concordia International Corp (CXR) Chart for Saturday, October, 21, 2017